CareDx Inc. (CDNA)
CareDx Inc. (CDNA) Stock Price, Analysis & Data
| Bid | 33.74 |
| Market Cap | 2.45B |
| Revenue (ttm) | 458.09M |
| Net Income (ttm) | 111.01M |
| Beta | 2.42 |
| EPS (ttm) | 2.08 |
| PE Ratio (ttm) | 22.75 |
| Forward PE | 34.92 |
| P/B (ttm) | 5.72 |
| P/S (ttm) | 5.34 |
| Earnings Date | Nov 3, 2026 |
| Ask | 60.27 |
| Volume | 984,911 |
| Avg. Volume (20D) | 1,030,296 |
| Open | 47.47 |
| Previous Close | 47.23 |
| Day's Range | 46.54 - 47.55 |
| 52-Week Range | 11.27 - 49.76 |
| Analyst | Buy |
| Price Target | 52 (9.91%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CDNA
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA so...
Financial Performance
In 2025, CareDx's revenue was 379.81M, an increase of 13.79% compared to the previous year's 333.79M. Earnings were -21.35M, a decrease of -140.64%.
Financial StatementsAnalyst Forecast
According to 6 analyst ratings, the average rating for CDNA stock is "Buy". The 12-month stock price forecast is 52, which is upside of 9.91% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
